Over the past two weeks, several large drug makers have either halted or rolled back prices as political pressure mounts on the pharmaceutical industry.
The moves suggest more than a little political posturing because the Trump administration is trying to follow through on implementing its so-called blueprint for lowering drug costs and, presumably, these companies hope to get something in return.
About the Author Reprints
